BIONXT SOLUTIONS INC. Cash Flow Conversion Efficiency
BIONXT SOLUTIONS INC. cash flow conversion efficiency. Based on the latest financial reports, BIONXT SOLUTIONS INC. (BXT) has a cash flow conversion efficiency ratio of 0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-588.29K ≈ $-687.77K USD) by net assets (€-7.32 Million ≈ $-8.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BIONXT SOLUTIONS INC. (2021–2025)
Cash flow conversion efficiency of BIONXT SOLUTIONS INC. from 2021 to 2025. This chart illustrates how BIONXT SOLUTIONS INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of BIONXT SOLUTIONS INC. for real-time trading data and today's change.
BIONXT SOLUTIONS INC. Cash Flow Conversion Ratio Explained
BIONXT SOLUTIONS INC. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BIONXT SOLUTIONS INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIONXT SOLUTIONS INC. ranked by their cash flow conversion efficiency. Also see BXT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Almaden Minerals Ltd
TO:AMM
|
-0.200x |
|
Bridger Aerospace Group Holdings, Inc. Common Stock
NASDAQ:BAER
|
-0.458x |
|
Blue Star Gold Corp
V:BAU
|
-0.344x |
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
0.091x |
|
Grand Kartech Tbk
JK:KRAH
|
0.061x |
|
Hennessy Capital Investment Corp. VII Ordinary Shares
NASDAQ:HVII
|
-0.001x |
|
LMS Co. Ltd
KQ:073110
|
-0.071x |
|
Bookook Steel
KO:026940
|
-0.006x |
Annual Cash Flow Conversion Efficiency for BIONXT SOLUTIONS INC. (2021–2025)
The table below shows the annual cash flow conversion efficiency of BIONXT SOLUTIONS INC. from 2021 to 2025. Review BIONXT SOLUTIONS INC. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-9.37 Million ≈ $-10.95 Million |
€-5.20 Million ≈ $-6.07 Million |
0.555x | +43.74% |
| 2024-12-31 | €-7.86 Million ≈ $-9.19 Million |
€-3.03 Million ≈ $-3.55 Million |
0.386x | -60.55% |
| 2023-12-31 | €-5.28 Million ≈ $-6.18 Million |
€-5.17 Million ≈ $-6.04 Million |
0.978x | -35.17% |
| 2022-12-31 | €-4.13 Million ≈ $-4.83 Million |
€-6.23 Million ≈ $-7.28 Million |
1.509x | +120.72% |
| 2021-12-31 | €1.67 Million ≈ $1.95 Million |
€-12.16 Million ≈ $-14.21 Million |
-7.284x | -- |
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-ag… Read more